In the preceding three months, 20 analysts have released ratings for Biomarin Pharmaceutical BMRN, presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 9 | 7 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 3 | 4 | 0 | 0 |
| 3M Ago | 3 | 4 | 3 | 0 | 0 |
Analysts have set 12-month price targets for Biomarin Pharmaceutical, revealing an average target of $89.25, a high estimate of $115.00, and a low estimate of $65.00. A 13.21% drop is evident in the current average compared to the previous average price target of $102.83.
Interpreting Analyst Ratings: A Closer Look
The analysis of recent analyst actions sheds light on the perception of Biomarin Pharmaceutical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Olivia Brayer | Cantor Fitzgerald | Maintains | Overweight | $90.00 | $90.00 |
| Akash Tewari | Wolfe Research | Announces | Outperform | $95.00 | - |
| David Lebovitz | Citigroup | Lowers | Neutral | $81.00 | $93.00 |
| Whitney Ijem | Canaccord Genuity | Lowers | Hold | $84.00 | $93.00 |
| Olivia Brayer | Cantor Fitzgerald | Lowers | Overweight | $90.00 | $110.00 |
| Jessica Fye | JP Morgan | Lowers | Overweight | $109.00 | $110.00 |
| Luca Issi | RBC Capital | Maintains | Sector Perform | $80.00 | $80.00 |
| Cory Kasimov | Evercore ISI Group | Lowers | Outperform | $105.00 | $115.00 |
| Eliana Merle | UBS | Raises | Buy | $106.00 | $104.00 |
| Joel Beatty | Baird | Lowers | Neutral | $65.00 | $72.00 |
| Danielle Brill | Raymond James | Announces | Outperform | $79.00 | - |
| Luca Issi | RBC Capital | Lowers | Sector Perform | $80.00 | $85.00 |
| Gena Wang | Barclays | Lowers | Overweight | $86.00 | $110.00 |
| George Farmer | Scotiabank | Lowers | Sector Perform | $78.00 | $95.00 |
| Joon Lee | Truist Securities | Lowers | Buy | $90.00 | $118.00 |
| Mohit Bansal | Wells Fargo | Lowers | Overweight | $90.00 | $115.00 |
| Luca Issi | RBC Capital | Lowers | Sector Perform | $85.00 | $100.00 |
| Geoff Meacham | B of A Securities | Lowers | Buy | $115.00 | $130.00 |
| Paul Matteis | Stifel | Lowers | Buy | $87.00 | $115.00 |
| William Pickering | Bernstein | Lowers | Outperform | $90.00 | $116.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Biomarin Pharmaceutical. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Biomarin Pharmaceutical compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Biomarin Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Biomarin Pharmaceutical's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Biomarin Pharmaceutical analyst ratings.
All You Need to Know About Biomarin Pharmaceutical
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Financial Milestones: Biomarin Pharmaceutical's Journey
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Biomarin Pharmaceutical's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 28.28%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Biomarin Pharmaceutical's net margin excels beyond industry benchmarks, reaching 14.22%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Biomarin Pharmaceutical's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.98% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Biomarin Pharmaceutical's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.52%, the company showcases efficient use of assets and strong financial health.
Debt Management: Biomarin Pharmaceutical's debt-to-equity ratio is below the industry average. With a ratio of 0.11, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Understanding the Relevance of Analyst Ratings
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
